ArticleBioresources and bioprocessing2025
Coupling optimization of cell growth cycle and key enzyme membrane localization for enhanced synthesis of high molecular weight heparosan by Corynebacterium glutamicum.
Article in Bioresources and bioprocessing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in chemoenzymatic synthesis of glycosaminoglycans and proteoglycans.Current opinion in chemical biology · 2026Review
- Enhanced heparosan biosynthesis in Corynebacterium glutamicum by systematic metabolic engineering and translation-level fine-tuning.Bioresources and bioprocessing · 2026Article
- Synthetic biology for heparin biomanufacturing.Bioresources and bioprocessing · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
High-molecular weight heparosan (HMW-heparosan) is a member of the glycosaminoglycan family. It possesses various chemical and physical properties suitable for a range of high-quality tissue engineering biomaterials, gels, scaffolds, and drug delivery systems. In this study, the HMW-heparosan biosynthesis pathway was engineered in Corynebacterium glutamicum through the introduction of heparosan synthase PmHS2 from Pasteurella multocida combined with overexpression of the key genes ugdA and galU, resulting in the generation of a stable HMW-heparosan-producing strain. Subsequently, to address metabolic flux competition, endogenous glycosyltransferases were systematically deleted to minimize UDP-glucose consumption, leading to a significant increase in HMW-heparosan accumulation. Additionally, cell growth was optimized by overexpressing transcriptional regulators whcD and PnkB, which was found to improve cell growth while creating an improved intracellular environment for biosynthesis. Notably, the critical enzyme heparosan synthase PmHS2 was relocated to the cell membrane by cell membrane display motifs porB, with its stability and catalytic efficiency being significantly enhanced so that the titer of HMW-heparosan reached 1.40 g/L in shake-flasks. Ultimately, the engineered strain was demonstrated to achieve HMW-heparosan production at 7.02 g/L with an average molecular weight (Mw) of 801 kDa in 5 L fed-batch bioreactor. These results demonstrate combinatorial optimization of cell factories, especially cell morphology and membrane localization of key enzymes, is efficacious and likely applicable for the production of other biopolymers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.